Global Congenital Abnormalities Market, By Type (Congenital Heart Disease, Down Syndrome, Cleft Lip and Cleft Palate, Spina Bifida, Club Foot, Phenylketonuria, Edward’s Syndrome, Others), Diagnosis (Preconception Screening, Neonatal Screening, Others), Treatment (Surgery, Additional Therapy, Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Congenital Abnormalities Market Analysis and Size
Birth defects are highly prevalent in highly populated regions. Every year, more than 40,000 babies are born with extreme birth defects. Conjoined twins, heart defects, cleft lip and palate and spina bifida are some of the major common birth defects. Around 2%-3% of infants develop more than one defect and the number rise to 5% by age one in the recent years. Congenital abnormalities cannot be associated with specific causes; there are so many reasons for the birth defects such as maternal nutritional status, family genetic history, environmental factors, socioeconomic and demographic factors, infections, and others.
Data Bridge Market Research analyses a growth rate in the congenital abnormalities market in the forecast period 2023-2030. The expected CAGR of congenital abnormalities market is tend to be around 4.50% in the mentioned forecast period. The market was valued at USD 153.6 million in 2022, and it would grow upto USD 218.4 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Congenital Abnormalities Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Congenital Heart Disease, Down Syndrome, Cleft Lip and Cleft Palate, Spina Bifida, Club Foot, Phenylketonuria, Edward’s Syndrome, Others), Diagnosis (Preconception Screening, Neonatal Screening, Others), Treatment (Surgery, Additional Therapy, Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Biora Therapeutics, Inc (U.S.), Boehringer Ingelheim International Gmbh (Germany), Amgen Inc. (U.S.), Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Novartis AG (Switzerland), Dr. Reddy’s Laboratories Ltd. (India)
|
|
Market Opportunities
|
|
Market Definition
Congenital abnormalities can be the functional and structural abnormalities such as metabolic disorder that occur during prenatal or intrauterine phase. It can be identified during prenatally, at birth time and many a times in the later phase. Congenital abnormalities can lead to the long term disabilities, that have key impact on the patient personal life, societies, families,and healthcare system.
Congenital Abnormalities Market Dynamics
Drivers
- Rising Awareness For Disease Treatment
Rising awareness among patients and several healthcare professionals for the treatment of different types of congenital syndromes and increasing usage of combination therapy are the major factors anticipated to boost the demand for market during the forecast period of 2023-2030.
- Tremendous Influence of Unhealthy lifestyle
Abnormal and unhealthy lifestyle makes the body prone to a wide range of infections and diseases. These infections directly or indirectly affect the wide functioning of numerous vital organs, hampers the general bodily processes. Huge consumption of alcohol and tobacco products can harm the sperm production and can cause bodily defects. This acts as one of the biggest factors of birth defects.
Opportunities
- Increasing Demand for Retail Pharmacies
The number of pediatric congenital athymia therapeutics being delivered through retail pharmacies and the number of retail pharmacies in highly developed countries create much opportunities for market growth. In addition, patients opt for retail pharmacies to purchase drugs, due to its easy accessibility.
- Increasing Incidence of Congenital Disorders
Congenital anomalies lead to around 25.3–38.8 million disability-adjusted life-years (DALYs) globally. WHO’s recent global burden of disease (GBD) study states that anomalies rank 17th in causes of disease burden. Only about six anomalies were allocated disability weights in the previous 2004 estimates, and new disability weights were not projected for congenital anomalies in 2012. Thus, it expands the growth of the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of proper healthcare professionals who are not much aware of the knowledge of the treatment methods for this disease could decrease the growth of the global congenital abnormalities market during the forecast period.
- Side Effects
The side effects associated with congenital abnormalities drugs which include headache, anxiety, and lack of awareness among people, will act as restrain and further impede the market's growth rate during the forecast period.
This congenital abnormalities market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the congenital abnormalities market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Congenital Abnormalities Market
According to the BMJ Journal article, there was an intense decline in the number of intensive new-born care globally. Though, there was an increase in the pregnancy rate and rate of birth defects, the congenital disabilities treatment facilities saw a reduction in their revenue due to the increased focus of the healthcare institutions towards treating COVID-19 infected patients. Lack of required infrastructural and institutional resources was majorly responsible for making revenue for congenital abnormalities market.
Global Congenital Abnormalities Market Scope
The congenital abnormalities market is segmented on the basis of type, diagnosis, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Congenital Heart Disease
- Down Syndrome
- Cleft Lip and Cleft Palate
- Spina Bifida
- Club Foot
- Phenylketonuria
- Edward’s Syndrome
- Others
Diagnosis
- Preconception Screening
- Neonatal Screening
- Others
Treatment
- Surgery
- Additional Therapy
- Drugs
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Congenital Abnormalities Market Regional Analysis/Insights
The congenital abnormalities market is analyzed and market size insights and trends are provided by type, diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the congenital abnormalities market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to increased government awareness programs, advanced technology and treatment.
Asia-Pacific dominates the market due to continuously increasing population resulting increasing prevalence of birth defect.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Congenital Abnormalities Market Share Analysis
The congenital abnormalities market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to congenital abnormalities market.
Key players operating in the congenital abnormalities market include:
- Johnson & Johnson Private Limited (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Biora Therapeutics, Inc (U.S.)
- Boehringer Ingelheim International Gmbh (Germany)
- Amgen Inc. (U.S.)
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Dr. Reddy’s Laboratories Ltd. (India)
SKU-